Principal Investigator/Program Director:
Klintmalm, Goran Bo Gustaf, M.D., Ph.D., F.A.C.S.

Ongoing Research Support

An Open-label randomized, prospective multicenter study to compare the efficacy and safety among three treatment regimens in patients receiving a liver transplant for end-stage liver disease caused by chronic hepatitis C infection
Baylor
2002 to Present

Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
Role: Principal Investigator
CKD-EPI, NIDDK, NIH
2002 to Present

Immunomonitoring of Transplant Patients
Baylor Department
2002 to Present

A Phase II, Open-Label, Multi-Center Study to Assess the Pharmacokinetics, Long-Term Safety and Tolerability of Tacrolimus in Stable Liver Transplant Patients Converted From a Prograf® Based Immunosuppression Regimen to a Modified Release (MR) Tacrolimus Based Immunosuppression
Astellas
2002 to Present

Liver Transplantation: Models for Patient Management and Resource Allocation
Mayo, NIH
2003 to Present

Donor T-Lymphocyte Chimerism in Liver Transplant Patients (The Persistence Of Donor Blood Cells In Patients Who Have Received A Liver Transplant)
Baylor
2003 to Present

Heidelberg Registry - Collaborative Transplant Study
Heldelberg
2003 to Present

A Multicenter, Prospective, Randomized Comparison of the Effectiveness of Custodiol HTK Solution with Viaspan UW Solution in the In-Situ Perfusion, Storage, and Transplantation of Cadaveric-Donor Kidneys and Livers
Odyssey
2003 to Present

A Randomized, Controlled, Multicenter Study of Thymoglobulin Induction Therapy with a Calcineurin-Inhibitor Sparing Regimen In Liver Transplant Patients
Genzyme
2004 to Present

A Facilitated Access Program to Provide Everolimus (RAD) for Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation
Novartis
2004 to Present

A Phase II Multicenter Trial to Assess the Safety and Efficacy of Campath-1H and Tacrolimus Followed by Immunosuppression Withdrawal in Liver Transplantation
Immune Tolerance / NIH
2004 to Present

Chronic Rejection Registry
International HLA Immunogenetics WS
2004 to Present

A 6 Month, Phase 2, Multicenter, Randomized, Open Label, Comparative Study Of 2 Dose Levels Of CP-690,550 Administered Concomitantly With Il 2 Receptor Antagonist Induction Therapy, Mycophenolate Mofetil And Corticosteroids Versus A Tacrolimus Based Immunosuppressive Regimen For The Prevention Of Allograft Rejection In De Novo Renal Allograft Recipients
Pfizer
2005 to Present

XM-ONE™ Endothelial Crossmatch Kit
AbSorber
2005 to Present

A Prospective OpenLabel, MultiCenter Randomized Trial of the Efficacy and Safety of a Long Term Calcineurin Inhibitor Free Maintenance Regimen with Mycophenolate Mofetil and Sirolimus in Recipients of an Orthotopic Liver Transplant
Roche
2005 to Present

A Multicenter Phase 2, Open Label Controlled, Extension Study for Stage 1 Subjects of Study A3921009 to Evaluate the Long Term Safety and Efficacy of CP-690,550 versus Tacrolimus when Co-Administered with Mycophenolate Mofetil in Renal Allograft Recipients
Pfizer
2005 to Present

Randomized Evaluation of Fibrosis Due to Hepatitis C after De Novo Liver Transplant - A Multicenter Randomized, Open Label Study to Compare the Development of Liver Fibrosis at 12 Months After Transplantation for Hepatitis C Cirrhosis in Patients Receiving Either Neoral or Tacrolimus
Novartis
2005 to Present

A Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II Intravenous, Single Dose, Dose Escalating Study of the Safety, Pharmacokinetics, and Efficacy of YSPSL for Prevention of Delayed Graft Function in Patients Undergoing Cadaveric Kidney Transplantation
Y's Therapeutics
2005 to Present

A Phase IIB, Randomized, Multicenter, Open-Label Concentration-Controlled, Safety Study of ISA247 and Tacrolimus (Prograf) in De Novo Renal Transplant Patients
Isotechnika
2005 to Present

Completed Research Support

An Open-Label Extension Study of the Safety of Long-Term Administration of Sirolimus (Rapamune) in Solid Organ Transplant Recipients
Wyeth-Ayerst Research
1998 to 2006

Cryptococcal Infection in Solid Organ Transplant Recipients: Correlating Clinical Characteristics and Outcome with Virulence, Tropism, and Immunosuppressive Agents
VA Pitts; NIH
2000 to 2006

A Multicenter, Randomized, Open-Label, Parallel Group Study To Compare Neoral with C-2h Monitoring to Tacrolimus with Trough Monitoring in DeNovo Liver Transplant Recipients
Novartis
2001 to 2005

One Year, Multicenter, Open-label, Prospective, Randomized Study to compare the effect of two Neoral C-2h maintenance targets, behond two months post transplant on renal function in the context of an immunosuppressive regimen consisting of Myfortic Simulect, and steroids
Novartis
2002 to 2005

A Randomized, Open-Label, Comparative Evaluation of Conversion from Tacrolimus to Sirolimus versus Continued use of Tacrolimus in Established Liver Allograft Recipients on Maintenance Therapy
Wyeth-Ayerst
2002 to 2005

Operational Tolerance Induction in Liver Translant Recipients Through a Preconditioning Regimen Including Thymoglobulin and Tacrolimus Monotherapy with Gene Chip Monitoring
Baylor
2002 to 2005

Pilot Trial of Operational Tolerance Induction in Liver Translant Recipients Through a Preconditioning Regimen Including Thymoglobulin and Tacrolimus Monotherapy with Gene Chip Monitoring
Baylor
2002 to 2005

Zenapax Pharmacokinetic Substudy
CTI
2003 to 2006

Mycophenolic Acid Pharmacokinetics Following Liver Transplantation Substudy to Protocol ZEN159: A Double Blind Randomized Study to Assess the Efficacy and Safety of Zenapax in Combination with CellCept, Tacrolimus and Corticiosteroids in Patients Undergoing Liver Transplantation
University of Penn
2003 to 2006

Systematic Collection of Data Regarding Combination Therapy with Voriconazole plus Caspofungin When Used for the Treatment of Invasive Aspergillosis in Solid Organ Transplant Recipients
VA Pitts, NIH
2003 to 2005

Safety, Tolerability and Efficacy Study of a Caspase Inhibitor, IDN-6556, in Patients Undergoing Orthotopic Liver Transplantation (OLT)
Idun Pharmaceuticals
2003 to 2005

Gene Diagnosis of Patient with Hyperoxaluria for its Clinical Implications on Future Treatment
None
2004 to 2005

Phase 1, Placebo-Controlled, Randomized, Sequential, Parallel-Group Dose Escalation Study to Evaluate 28-Day Multiple Dose Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CP 690,550 in Stable Renal Allograft Recipients
Pfizer
2004 to 2004

Treatment Protocol for Exceptional Use of A Caspase Inhibitor in Patients Undergoing Orthotopic Liver Transplantation
Idun Pharmaceuticals
2004 to 2005

More about Dr. Goran Bo Gustaf Klintmalm

Dr. Klintmalm's publications